Literature DB >> 1809075

Steroid receptor assays: an Italian quality assessment program.

A Piffanelli1, G Giovannini, D Pelizzola, M De Bortoli, L Catozzi, M Giganti.   

Abstract

An Italian Committee for the quality assessment of steroid receptor assay was instituted in 1979; the number of laboratories participating in this program increased from 7 in 1979 to 43 in 1989. The Italian program in collaboration with EORTC (European Organization Research and Treatment of Cancer) initiatives, utilizes as working standards lyophilized samples that tolerate prolonged storage at 4 degrees C. The national representatives agreed, according to EORTC, that all laboratories would perform, for measurement of steroid receptors, the dextran coated charcoal (DCC) method using the same concentration of radioactive ligands (3-H-estradiol, 3-H-ORG-2058) and would determine the non-specific binding with the same compounds (diethylstilbestrol and ORG-2058). The computation method is a potential source of interlaboratory variation; the multipoint Scatchard analysis, though difficult to apply for receptor problems, is the most widely used approach at present. The standardized DCC method is the most common and recognized (Food and Drug Administration) procedure for quantifying hormone receptor in human cancer. Since new technologies are being introduced (receptor enzyme immunoassay, EIA), adequate programs of quality assessment are required; in general, it has demonstrated an excellent correlation between radioligand binding assay (DCC) and immunochemical assay (EIA). Other prognostic factors, such as proteins produced by oncogenes and growth factors of the malignant cells have become more important. Some of these factors, as well as estrogen receptor status, seem the major determinants of recurrence after the first treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1809075

Source DB:  PubMed          Journal:  Ann Ist Super Sanita        ISSN: 0021-2571            Impact factor:   1.663


  2 in total

1.  Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen.

Authors:  D Coradini; E Biganzoli; C Pellizzaro; S Veneroni; S Oriana; F Ambrogi; R Erdas; P Boracchi; M G Daidone; E Marubini
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

2.  miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.

Authors:  Elisabetta Crippa; Lara Lusa; Loris De Cecco; Edoardo Marchesi; George Adrian Calin; Paolo Radice; Siranoush Manoukian; Bernard Peissel; Maria Grazia Daidone; Manuela Gariboldi; Marco Alessandro Pierotti
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.